This educational activity provides clinicians with an overview of current best practices and emerging clinical trial data related to the use of bispecific antibodies in the diagnosis, screening, and management of relapsed/refractory B-cell non-Hodgkin lymphomas (R/R B-NHLs), with a focus on safety considerations and adverse event management.

RELEASED DATE: January 06, 2026
EXPIRATION DATE: January 06, 2027

Non-Hodgkin’s Lymphoma accounts for about 4% of cancers in the US. It also affects the VA population and is majorly caused due to exposure to toxic substances. In this podcast, we will discuss the current treatments, adverse events and management of VA NHL patients. We will cover diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL).

RELEASED DATE: January 25, 2024
EXPIRATION DATE: January 25, 2025

This CME activity will provide hematologists and oncologists with practical, case-based insights into the management of patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma, with a special focus on follicular lymphoma (R/R FL). Expert faculty will review prognostic tools and clinical features, including early relapse, to guide risk stratification and inform treatment planning. The program will highlight the role of bispecific antibody therapies, with an emphasis on integrating clinical trial data into personalized care strategies. Special attention will be given to proactive recognition, grading, and management of toxicities, particularly cytokine release syndrome, as well as best practices in infection prophylaxis and monitoring. Through didactic discussion, illustrative case study, and whiteboard animation, learners will gain strategies to optimize outcomes and safely implement bispecific therapies for patients with R/R FL.

RELEASED DATE: August 29, 2025
EXPIRATION DATE: August 29, 2026

These podcasts are designed to help healthcare professionals assess the relationship between checkpoint inhibition and immunopathology in advanced melanoma, update them on the latest clinical data with anti-LAG3 antibody combinations in advanced melanoma, and provide strategies to optimize the safety of combination immunotherapy approaches in advanced melanoma. Additionally, healthcare professionals will be able to understand the importance of patient advocacy as we converse with a patient about their cancer diagnosis and treatment.

RELEASED DATE: April 21, 2023
EXPIRATION DATE: April 21, 2024

This program will dive into the latest advances in the management of non-melanoma skin cancers (NMSCs), including new data presented at ESMO. Through real-world clinical cases, faculty will guide participants in applying emerging evidence—particularly regarding neoadjuvant and adjuvant immune checkpoint inhibitors—to personalize treatment based on patient- and disease-specific risk factors. The session will also emphasize shared decision-making and multidisciplinary care to support coordinated, patient-centered treatment planning for individuals with advanced NMSCs.

RELEASED DATE: November 21, 2025
EXPIRATION DATE: November 21, 2026

This educational series is tailored for VA healthcare providers managing patients with advanced melanoma, focusing on the unique needs of the Veteran population. The program equips clinicians with practical strategies to identify veterans requiring prompt screening based on patient-specific and military service-related factors. Participants will gain a deeper understanding of aberrant signaling pathways in melanoma pathogenesis and the mechanistic rationale for targeted therapies and immunotherapies. The series also highlights combination immunotherapy regimens that have reshaped first-line treatment for advanced melanoma, reviewing current and emerging efficacy and safety data for immune checkpoint inhibitors, including anti-PD-1, anti-CTLA-4, and anti-LAG-3 agents. Clinicians will gain insight into best-practices for treatment selection and interdisciplinary collaboration within the melanoma Patient-Aligned Care Team (PACT) to deliver personalized, guideline-aligned, Veteran-centered oncology care.

RELEASED DATE: January 12, 2026
EXPIRATION DATE: January 12, 2027

This activity aims to enhance clinicians’ expertise in managing lung cancer in veterans by improving their ability to implement effective lung cancer screening strategies, apply precision oncology through biomarker-driven approaches, select appropriate targeted therapies across various stages of NSCLC treatment, and optimize patient outcomes by proactively addressing immune-related adverse effects associated with immune checkpoint inhibitor therapy.

RELEASED DATE: January 06, 2026
EXPIRATION DATE: January 06, 2027

This program will unpack the latest clinical insights in NSCLC, including newly presented data from ESMO on ICI monotherapy and combination strategies. Through real-world clinical cases, participants will apply emerging efficacy, safety, and biomarker evidence to personalize treatment plans and strengthen proactive approaches for monitoring and managing immune-related adverse events. Faculty will guide learners in translating rapidly evolving science into practical, patient-centered decision-making across the lung cancer care continuum.

RELEASED DATE: November 21, 2025
EXPIRATION DATE: November 21, 2026

This program is designed to address persistent clinical gaps in the management of nonmelanoma skin cancers (NMSCs), particularly in identifying and treating high-risk disease. The program is structured to improve clinicians’ knowledge, competence, and confidence by enabling them to identify key diagnostic and stratification criteria to promptly and accurately recognize high-risk NMSC. Building on this foundation, the education integrates current clinical data for emerging neoadjuvant and adjuvant immunotherapies, supporting clinicians in incorporating these approaches into treatment strategies to optimize surgical outcomes and reduce recurrence risk. Additionally, the program emphasizes the importance of coordinated, patient-centered care by developing strategies for clinicians to work effectively within the multidisciplinary team and engage patients in shared decision-making, ultimately enhancing communication, care alignment, and overall outcomes in high-risk NMSC management.

RELEASED DATE: May 30, 2026
EXPIRATION DATE: May 30, 2027

This CME-accredited micro-learning activity introduces healthcare professionals to an immersive AR Mobile Application designed to enhance patient-centered care in relapsed/refractory multiple myeloma (R/R MM). Through a brief faculty-led demonstration, learners will explore the practical use of AR technology to reinforce clinical concepts, support shared decision-making, and improve communication with patients and colleagues.

RELEASED DATE: May 30, 2026
EXPIRATION DATE: May 30, 2027